Volume 6, Issue 1, February Issue - 2018, Pages:220-229
|Authors: Ohoud A. Alomari, Taha A.Kumosani, Archana P. Iyer, EtimadA. Huwait, Mohammed S. Bamaga, Naglaa M. Salim, Charles G. Glabe|
|Abstract: To determine the possible associations between antioxidant serum markers and apolipoprotein E (APOE) genotypes in an elderly demented Saudi population.|
There were 80 subjects included in this study classified according to cognitive function as two groups control and demented patients. Antioxidant capacity and lipid peroxidation were measured using spectrophotometric analysis. APOE genotypes were determined using restriction enzyme analysis. Correlations of serum levels of antioxidant capacity and lipidperoxidation with APOE genotypes were assessed. Serum antioxidant capacity was significantly reduced in patients group in comparison to the control (p-value= 0.0125< 0.05). Also, lipid peroxidation level showed significantly higher concentration on patient compared to control group (p-value=0.0167?0.05). For APOE, three alleles (E2, E3 and E4) and four genotypes (E2/3, E3/3, E3/4 and E4/4) were identified in present study. There was a significant different between alleles and genotypes distribution in the study groups as the frequency of E4 was higher in the subjects with dementia compare toin control (p-value=0.0168?0.05) and (p-value=0.0447?0.05), respectively. However, no association was found between APOE status and serum levels of antioxidant capacity and lipid peroxidation. In conclusion, no correlation between antioxidant capacity or lipid peroxidation levels and APOE genotypes. They are independent risk factors for dementia in the Saudi population.
Al-Khedhairy AAA (2004) Apolipoprotein E polymorphism as a predictor for cognitive decline and dementia in the Saudi general population over 65 years. Genetics and Molecular Biology 27: 331-334.
American Psychatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5®)Arlington: American Psychiatric Publishing.
Alzheimer's Association (2017) 2017 Alzheimer's disease facts and figures. Alzheimer's & Dementia 13: 325-373.
Awad N, El-Tarras A (2011) Analysis of the APO B R3500Q mutation and APOE polymorphism in Taif Saudi population using polymerase chain reaction-reveres hybridization technique. Journal of Molecular Biomarkers & Diagnosis 2: 109. doi:10.4172/2155-9929.1000109.
Baldeiras I, Santana I, Proença MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR (2008) Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. Journal of Alzheimer's Disease 15: 117-128.
Benzie IF, Strain JJ (1996)The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Analytical Biochemistry 239: 70-76.
Bertram L, Tanzi RE (2008) Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nature Reviews Neuroscience 9: 768-778.
Borenstein AR, Mortimer JA, Ding D, Schellenberg GD, DeCarli C, Zhao Q, Copenhaver C, Guo Q, Chu S, Salmon DP, Galasko D (2010) Effects of apolipoprotein E-ε4 and-ε2 in amnestic mild cognitive impairment and dementia in Shanghai: SCOBHI-P. American Journal of Alzheimer's Disease & Other Dementias 25: 233-238.
Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig L S, Marder K (2014) Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human molecular genetics 23: 6139-6146.
Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nature Reviews Neuroscience 10: 333-344.
Cacabelos R (2008) Pharmacogenomics in Alzheimer's disease. Pharmacogenomics in Drug Discovery and Development: From Bench to Bedside 448: 213-357.
Castro-Chavira S, Fernandez T, Nicolini H, Diaz-Cintra S, Prado-Alcala R (2015). Genetic markers in biological fluids for aging-related major neurocognitive disorder. Current Alzheimer Research 12: 200-209.
Cervellati C, Romani A, Seripa D, Cremonini E, Bosi C, Magon S, Passaro A, Bergamini CM, Pilotto A, Zuliani G (2014) Oxidative balance, homocysteine, and uric acid levels in older patients with Late Onset Alzheimer's Disease or Vascular Dementia. Journal of the neurological sciences 337 : 156-161.
Chang YT, Chang WN, Tsai NW, Huang CC, Kung CT, Su YJ, Lin WC, Cheng BC, Su CM, Chiang YF, Lu CH (2014) The roles of biomarkers of oxidative stress and antioxidant in Alzheimer’s disease: a systematic review. BioMed research International, 10.1155/2014/182303.
Chen KL, Sun YM, Zhou Y, Zhao QH, Ding D, Guo QH (2016) Associations between APOE polymorphisms and seven diseases with cognitive impairment including Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies in southeast China. Psychiatric genetics 26: 124.
Chico L, Simoncini C, Lo Gerfo A, Rocchi A, Petrozzi L, Carlesi C, Volpi L, Tognoni G, Siciliano G, Bonuccelli U (2013) Oxidative stress and APO E polymorphisms in Alzheimer's disease and in mild cognitive impairment. Free radical research 47: 569-576.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GA, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261: 921-923.
Cristalli DO, Arnal N, Marra FA, de Alaniz MJ, Marra CA (2012) Peripheral markers in neurodegenerative patients and their first-degree relatives. Journal of the neurological sciences, 314: 48-56.
D’Onofrio G, Sancarlo D, Seripa D, Ricciardi F, Giuliani F, Panza F, Greco A (2016) Non-Pharmacological Approaches in the Treatment of Dementia. In Update on Dementia: InTech 10.5772/64232
Dewji NN, Singer SJ (1996) Genetic clues to Alzheimer's disease. Science 271: 159.
Dose J, Huebbe P, Nebel A, Rimbach G (2016) APOE genotype and stress response-a mini review. Lipids in health and disease 15: 121.
Emi M, Wu LL, Robertson MA, Myers RL, Hegele RA, Williams RR, White R, Lalouel JM (1988) Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics 3: 373-379.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, Van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. Jama 278: 1349-1356.
Ferencz B, Gerritsen L. Genetics and underlying pathology of dementia (2015) Genetics and underlying pathology of dementia. Neuropsychology review 25: 113-124.
Frieden C, Garai K (2012) Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer’s disease. Proceedings of the National Academy of Sciences 109: 8913-8918.
Friedman J (2011) Why is the nervous system vulnerable to oxidative stress? In Oxidative stress and free radical damage in neurology. Springer 10.1007/978-1-60327-514-9_2: 19-27.
Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron P, Bresolin N, Scarpini E (2006) Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiology of aging 27: 262-269.
Halliwell B, Gutteridge JM (2015) Free radicals in biology and medicine. Oxford University Press, USA (Ed. 5).
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature genetics 41: 1088-1093.
Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor perspectives in medicine 2 : a006312.
Huang Y (2010) Aβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends in Molecular Medicine 16 : 287-294.
Huang Y, Mahley RW (2014) Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiology of Disease 72: 3-12.
Ihara Y, Hayabara T, Sasaki K, Kawada R, Nakashima Y, Kuroda S (2000) Relationship between oxidative stress and apoE phenotype in Alzheimer's disease. Acta neurologica scandinavica 102 : 346-349.
Iova A, Micle O, VICA? L, Micle L, Iova S, MURE?AN M, IONI?? CA (2014) Oxidative stress in Alzheimer’s dementia. Age 50:58.
Jedenius E, Wimo A, Strömqvist J, Fastbom J, Winblad B, Winblad U, Andreasen N (2015) Comparing estimated cost per patient for dementia care: Two municipalities and Swedish national population data. Clinical Nursing Studies 3: 67.
Jellinger KA (2007) The enigma of mixed dementia. Alzheimer's & Dementia 3: 40-53.
Kang R, Li P, Wang T, Li X, Wei Z, Zhang Z, Zhong L, Cao L, Heckman MG, Zhang YW, Xu H (2016) Apolipoprotein E epsilon 2 allele and low serum cholesterol as risk factors for gastric cancer in a Chinese Han population. Scientific Reports 6. doi: 10.1038/srep19930.
Leduc V, Domenger D, De Beaumont L, Lalonde D, Bélanger-Jasmin S, Poirier J (2011) Function and comorbidities of apolipoprotein e in Alzheimer's disease. International Journal of Alzheimer’s Disease 2011: 974361, DOI: http://dx.doi.org/10.4061/2011/974361.
Lee AY (2011) Vascular dementia. Chonnam Medical Journal 47: 66-71.
Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology 9: 106-118.
López-Riquelme N, Alom-Poveda J, Viciano-Morote N, Llinares-Ibor I, Tormo-Díaz C (2016) Apolipoprotein E ε4 allele and malondialdehyde level are independent risk factors for Alzheimer’s disease. SAGE open medicine 4: 2050312115626731.
Luca M, Luca A, Calandra C (2015) The role of oxidative damage in the pathogenesis and progression of Alzheimer’s disease and vascular dementia. Oxidative medicine and cellular longevity 2015: 504678. doi: 10.1155/2015/504678..
Lundkvist J, Halldin MM, Sandin J, Nordvall G, Forsell P, Svensson S, Jansson L, Johansson G, Winblad B, Ekstrand J (2014) The battle of Alzheimer’s Disease–the beginning of the future Unleashing the potential of academic discoveries. Frontiers in pharmacology 5: 102. doi: 10.3389/fphar.2014.00102..
Mahley RW, Huang Y (2012) Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 76: 871-885.
Mahley RW, Huang Y, Weisgraber KH (2006) Putting cholesterol in its place: apoE and reverse cholesterol transport. Journal of Clinical Investigation 116: 1226.
Moslemnezhad A, Mahjoub S, Moghadasi M (2016) Altered plasma marker of oxidative DNA damage and total antioxidant capacity in patients with Alzheimer's disease. Caspian Journal of Internal Medicine 7 :88.
Negahdar H, Hosseini SR, Parsian H, Kheirkhah F, Mosapour A, Khafri S, Haghighi AH (2015) Homocysteine, trace elements and oxidant/antioxidant status in mild cognitively impaired elderly persons: a cross-sectional study. Romanian Journal of Internal Medicine 53: 336-342.
Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, Filip M (2016) Oxidative stress in neurodegenerative diseases. Molecular Neurobiology 53: 4094-4125.
Panza F, Frisardi V, Seripa D, D’Onofrio G, Santamato A, Masullo C, Logroscino G, Solfrizzi V, Pilotto A (2012) Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. Ageing research reviews 11: 87-103.
Percy M, Somerville MJ, Hicks M, Colelli T, Wright E, Kitaygorodsky J, Jiang A, Ho V, Parpia A, Wong MK, Garcia A (2014) Risk factors for development of dementia in a unique six-year cohort study. I. An exploratory, pilot study of involvement of the E4 allele of apolipoprotein E, mutations of the hemochromatosis-HFE gene, type 2 diabetes, and stroke. Journal of Alzheimer's Disease 38: 907-922.
Pham-Huy LA, He H, Pham-Huy C (2008) Free radicals, antioxidants in disease and health. International Journal of Biomedical Science 4: 89.
Popa-Wagner A, Mitran S, Sivanesan S, Chang E, Buga AM (2013) ROS and brain diseases: the good, the bad, and the ugly. Oxidative medicine and cellular longevity 2013: 963520, http://dx.doi.org/10.1155/2013/963520.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's & Dementia 9: 63-75. e62.
Pulido R, Jiménez-Escrig A, Orensanz L, Saura-Calixto F, Jiménez-Escrig A (2005) Study of plasma antioxidant status in Alzheimer's disease. European Journal of Neurology 12: 531-535.
Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, Wagner E (2008) Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. Journal of Neuroscience 28: 11445-11453.
Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM (2012) Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Archives of Neurology 69: 757-764.
Rohn TT (2014) Is apolipoprotein E4 an important risk factor for vascular dementia? International journal of clinical and experimental pathology 7: 3504.
Rosini M, Simoni E, Minarini A, Melchiorre C (2014) Multi-target design strategies in the context of Alzheimer’s disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochemical Research 39 : 1914-1923.
Rubino E, Vacca A, Govone F, De Martino P, Pinessi L, Rainero I (2013) Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: a meta-analysis. Alzheimer's & Dementia 9 : 706-713.
Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, Squitti R, Perry G (2013) Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis. Neurobiology of Disease 59: 100-110.
Sekler A, Jiménez JM, Rojo L, Pastene E, Fuentes P, Slachevsky A, Maccioni RB (2008) Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism. Neuropsychiatric Disease and Treatment 4 : 715.
Thakur ME (2015) The American psychiatric publishing textbook of geriatric psychiatry: American Psychiatric Publishing. ISBN 1585624845, 9781585624843.
Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. The Lancet Neurology 10: 241-252.
Villeneuve S, Brisson D, Marchant NL, Gaudet D (2014) The potential applications of Apolipoprotein E in personalized medicine. Frontiers in Aging Neuroscience 6: 154. doi: 10.3389/fnagi.2014.00154.
Vos SJ, Van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L (2013). Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 80: 1124-1132.
Walker Z, Possin KL, Boeve BF, Aarsland D (2015) Lewy body dementias. The Lancet 386 : 1683-1697.
Wang Z, Ma W, Rong Y, Liu L (2014) The association between apolipoprotein E gene polymorphism and mild cognitive impairment among different ethnic minority groups in China. International Journal of Alzheimer’s Disease 2014: 150628. doi: 10.1155/2014/150628.
Williams JW, Plassman BL, Burke J, Holsinger T, Benjamin S (2010) Preventing Alzheimer's disease and cognitive decline. Evidence report/technology assessment No. 193.(Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I.) AHRQ Publication No. 10-E005. InAHRQ Publication No. 10-E005 2010. Agency for Healthcare Research and Quality Rockville, MD.
World Health Organization (2012) Dementia: Fact Sheet Number 362. Retreived from: http://www. who. int/mediacentre/factsheets/fs362/en.
Yan W, Wei P, Xuan Y, Guo Y, Li X, Song Y, Fang K (2016) Relationship between apolipoprotein E gene polymorphism and Parkinson’s disease: a meta-analysis. International Journal of Clinical and Experimental Medicine 9: 5334-5346.
Zafrilla P, Mulero J, Xandri JM, Santo E, Caravaca G, Morillas JM (2006) Oxidative stress in Alzheimer patients in different stages of the disease. Current medicinal chemistry 13: 1075-1083.
Zhou Q, Peng D, Yuan X, Lv Z, Pang S, Jiang W, Yang C, Shi X, Pang G, Yang Y, Xie H (2014) APOE and APOC1 gene polymorphisms are associated with cognitive impairment progression in Chinese patients with late-onset Alzheimer's disease. Neural Regeneration Research 9: 653.
Zito G, Polimanti R, Panetta V, Ventriglia M, Salustri C, Siotto MC, Moffa F, Altamura C, Vernieri F, Lupoi D, Cassetta E (2013) Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia. Rejuvenation Research 16: 51-56.
Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature Reviews Neuroscience 12: 723-738.